Story

Oracle Shares Rise After Report Cites Lead in Japan Cloud Contract Race

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Oracle Shares Rise After Report Cites Lead in Japan Cloud Contract Race

Summary

Oracle's stock gained in premarket trading following a Financial Times report that the company is the frontrunner in discussions to provide cloud infrastructure services to the Japanese government.

Text size
Background

Oracle (NYSE: ORCL) shares climbed 1.4% in premarket trading on Monday after a report indicated the company is leading rivals in a bid to secure a major cloud services contract with the Japanese government.

Report Details

The Financial Times, citing seven people familiar with the discussions, reported that Oracle is ahead of competitors Amazon Web Services (AWS), Microsoft, and Google for the government cloud infrastructure deal. However, the report stressed that a final decision has not been made.

Two people familiar with the situation told the publication that Japan could still opt to split the contract among multiple providers. According to the Financial Times, Oracle, Microsoft, Google, and the Japanese prime minister’s office all declined to comment. AWS told the outlet that it engages with all customers, including the Japanese government, to meet their specific security and sovereignty needs.

Sample IUX Markets – In-articleAd

Market Implications

A potential contract with the Japanese government would represent a significant win for Oracle's cloud business as it seeks to gain market share from larger competitors. Government cloud contracts are highly sought-after and typically come with stringent security and data sovereignty requirements, making them a key validation of a provider's capabilities.

This development is a crucial test in the competitive landscape of enterprise cloud services. Oracle has been investing heavily to expand its Oracle Cloud Infrastructure (OCI) to better compete with market leaders AWS and Microsoft Azure. Securing a national government contract in a major economy like Japan would bolster its reputation and could help attract other large enterprise and public sector clients.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST